Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:

“That half of women in England with...

New research findings published in the New England Journal of Medicine, that found that pembrolizumab, if given in combination with chemotherapy before surgery,...

The Scottish Medicines Consortium (SMC) has today announced its decision to recommend two new treatments – trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa...

A woman stands near a busy London road with a megaphone
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

As 2021 comes to a close, we wanted to highlight some of the key issues we’ve been campaigning on this year, as well as some big wins we’ve secured together. 

Philippa
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

Earlier this year, we launched a campaign to ensure all eligible patients can access Trodelvy, an exciting new drug that could give some people living with incurable breast cancer the hope of more time. 

PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

In this blog, we will look at the work we are doing alongside a coalition of over 50 health organisations, including Cancer Research, Macmillan Cancer Support, and The Health Foundation, to influence the Health and Care Bill, and why it matters for people affected by breast cancer.

Anna, who has bobbed brown hair, smiles while holding up a medal from one of her many races. She is wearing a bright pink top.
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

In October 2021, we were very disappointed to learn that the National Institute for Health and Care Excellence (NICE) was provisionally unable to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS.

A group of women meeting at parliament in order to speak with MPs about secondary breast cancer
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

We’re committed to improving treatment, care and services for people living with secondary breast cancer, which is why it’s a central part of our new strategy. 

A split image showing Holly, a young woman with long dark hair, and Edd, a young man with short curly hair
PUBLISHED ON: PUBLISHED: 25 May 2017 UPDATED: 8 February 2022

Ever wondered how new drugs get tested and approved? This week, we'll be hearing from Edd and Holly about how substances go from lab experiments to licensed treatments.

The National Institute for Health and Care Excellence (NICE) has today (Thursday 12th August 2021) announced its decision to approve abemaciclib with fulvestrant...